0.60Open1.74Pre Close12 Volume12 Open Interest7.50Strike Price696.00Turnover82.37%IV8.57%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.48Extrinsic Value100Contract SizeAmericanOptions Type0.5140Delta0.3115Gamma15.31Leverage Ratio-0.0166Theta0.0015Rho7.87Eff Leverage0.0062Vega
Foghorn Therapeutics Stock Discussion
loading...
loading...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet